The Indian Pharmaceutical Alliance (IPA) has come up with a proposal for upgradation of the regulatory infrastructure to make the domestic pharmaceutical industry more competitive in the wake of the post-patent realities.
According to IPA, an industry body of 11 research-based pharmaceutical companies, India should harmonise standards for registration of new drugs and sources of supply with those of the regulated markets.
